All News
Biologics Do Not Increase Melanoma Risk
Rheumatoid arthritis (RA) patients have a higher risk of certain cancers (e.g., skin, lung, lymphoma). At issue is whether the newer agents modify this risk appreciably.
Read Article
The RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read Article
Rheumatic Manifestations Following Chikungunya Infection
In the Makonde language, “Chikungunya” translates to “that which bends up”, descriptive of the twisted posture of those infected secondary to intense joint and muscle pain experienced during the acute phase of the disease.
Read Article
Sjogren's Syndrome Foundation's 2017 Sjogren's Treatment Guidelines
Dr. Steven Carsons and an expert committee of the Sjogren's Syndrome Foundation have published a clinical practice guidelines (CPGs) and recommendations for the managment of Sjögren's syndrome.
Read Article
Gadolinium Accumulation with Repeated MRI
Clinical Rheumatology reports that the repeated intravenous administration of gadolinium-based contrast agents (GBCAs), although clinically useful, may be associated with rare toxicity and the uncertain clinical effects of accumulation.
Read Article
Checkpoint Inhibitors Causing Rheumatic Disease
Calabrese and Velcheti have reviewed the current understanding that underlies a new drug-induced rheumatic disease - checkpoint inhibitor arthritis and autoimmune disease.
Read Article
FDA Invites Open Commentary on Biosimilar Interchangeability
In January 2017, the Food and Drug Administration (FDA) released its draft guidance on the issue of interchangeability between biosimilars and originator biologic drugs. The window for your input will close on May 18, 2017. RheumNow encourages you to participate in this exercise and express your opinion.
Read Article
The RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read Article
European Biologic Manufacturers Issue Warnings About Biosimilar Switching
Reuters has reported that European drugmakers have taken the tact of warning EU physician contemplating the switch from existing (originator) biologic therapy to newer, cut-rate biosimilar. Biosimilar use is widespread outside the USA.
Read Article
Oral Bacteria Driving ACPA and Rheumatoid Arthritis
The current JAMA has a perspective piece on the role of the oral microbiome in the pathogenesis and references a recent article by Konig et al on "Aggregatibacter actinomycetemcomitans–induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis (RA)." (Citation
Read Article
Non-Ischemic Heart Failure in Rheumatoid Arthritis
The current issue of the Journal of the American College of Cardiology reports on the relative risk of heart failure (HF) in rheumatoid arthritis (RA) and its relation to ischemic heart disease (IHD).
Read Article
Methotrexate and Folate Use by Rheumatologists - Survey Results
The February 2017 RheumNow “Live Vote” surveyed US and non-US rheumatologists about their beliefs and practices regarding folic acid and methotrexate (MTX) use. A total of 495 responses were tabulated in 2 weeks. Here are the results, and comments from Dr. Kremer on his preferred answers to these questions.
Read Article
Psychologic Impact of Rheumatoid Arthritis on Men
Arthritis Care & Research has reported the results of a study that analyzed the perceptions and attitudes of men afflicted with rheumatoid arthritis (RA). The results are drawn from a series of focus groups involving 22 men with RA.
Read Article
Novel Mechanisms for Rheumatoid Arthritis
The Journal of Leukocyte Biology has reported mechanisms whereby synovial CD4+ T cells producing IL-21 can contribute to the pathogenesis of RA by activating synovial fibroblasts.
Read Article
Rheumatoid Progression Slowing Down
Patients with early rheumatoid arthritis (RA) with onset in the modern era had significantly lower baseline and annual rates of radiographic disease progression versus those with onset before 2001, researchers in England reported.
Read Article
High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
Despite recent advances in treatment of rheumatoid arthritis (RA), MANY patients on existent biological therapy fail to achieve remission. Therapies with novel mechanisms of actions, great efficacy and well balanced safety profile remain an unmet need.
Read Article
The RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
Higher Hip and Knee Replacement Revision Rates in Younger Patients
Joint arthroplasty has grown into a billion dollar industry worldwide. However, optimal timing and the success of total joint replacements in younger patient groups has not been well studied.
Read Article
Sirukumab Effective in Rheumatoid Arthritis
Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 (IL-6) and is being developed for use in rheumatoid arthritis (RA) and other inflammatory diseases.
Read Article
Quarter of Patients Claim Diet Influences Their Rheumatoid Arthritis
Patients often characterize certain foods as “inflammatory” or “anti-inflammatory” as they combat their arthritis.
Read Article
